Moleculin to Present at the Life Sciences Investor Forum
March 24 2020 - 7:30AM
Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the
“Company”), a clinical stage pharmaceutical company with a broad
portfolio of drug candidates targeting highly resistant tumors,
today announced that Walter Klemp, Chairman and Chief Executive
Officer, will present at the Life Sciences Investor Forum being
held online at LifeSciencesInvestorForum.com on March 26th.
Details of the presentations are below:
Event: |
Life Sciences
Investor Forum |
Date: |
March 26, 2020 |
Time: |
11:30 – 12:00 PM ET |
Link: |
https://tinyurl.com/032620LSIF |
This will be an interactive online event where
investors are invited to ask the company questions in real-time. If
attendees are not able to join on the day of the conference, an
archived webcast will also be made available after the event.
It is recommended that investors pre-register
and run the online system check to expedite participation and
receive event updates.
Learn more about the event at
www.lifesciencesinvestorforum.com.
About Moleculin Biotech,
Inc.
Moleculin Biotech, Inc. is a clinical stage
pharmaceutical company focused on the development of a broad
portfolio of oncology drug candidates for the treatment of highly
resistant tumors. The Company's clinical stage drugs are:
Annamycin, a Next Generation Anthracycline, designed to avoid
multidrug resistance mechanisms with little to no cardiotoxicity
being studied for the treatment of relapsed or refractory acute
myeloid leukemia, more commonly referred to as AML, WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic cancer
and hematologic malignancies, and WP1220, an analog to WP1066, for
the topical treatment of cutaneous T-cell lymphoma. Moleculin is
also engaged in preclinical development of additional drug
candidates, including additional Immune/Transcription Modulators,
as well as compounds capable of Metabolism/Glycosylation
Inhibition.
For more information about the Company, please
visit http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Annamycin to
continue to show safety and efficacy in patients and whether the
level of activity and lack of toxicity experienced in the Company’s
current trials can be demonstrated in a larger patient population.
Although Moleculin believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Moleculin Biotech has attempted to identify forward-looking
statements by terminology including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. "Risk Factors" in our most recently filed Form 10-K
filed with the Securities and Exchange Commission ("SEC") and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
Contacts James Salierno / Carol Ruth The Ruth
Group 646-536-7028 / 7000
jsalierno@theruthgroup.com
cruth@theruthgroup.com
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moleculin Biotech (NASDAQ:MBRX)
Historical Stock Chart
From Sep 2023 to Sep 2024